



TFS CORPORATION

UBS Food and Agribusiness Conference

30 November 2016



Important Notice and Disclaimer

This presentation contains general information only and does not take into account the investment objectives, financial situation and particular needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser, lawyer, accountant, tax or such other adviser as considered appropriate having regard to their objectives, financial situation and needs before taking any action.

The information in this presentation contains historic information about the performance of TFS and securities in TFS (or any other financial product). That information is historic only, and is not an indication or representation about the future performance of TFS or securities in TFS (or any other financial product).

This presentation may contain forward-looking statements regarding our intent, belief or current expectations with respect to TFS' business and operations, market conditions, results of operations and financial condition, specific provisions and risk management practices. When used in this presentation, the words 'plan', 'will', 'anticipate', 'expect', 'may', 'should' and similar expressions, as they relate to TFS and its management, are intended to identify forward-looking statements. Forward looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of TFS to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.

No representation or warranty, express or implied, is given as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation.

To the maximum extent permitted by law, TFS and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising in negligence, statute or otherwise) for any direct or indirect loss or damage which may arise or be suffered by any person through use or reliance on anything contained in, or omitted from, this presentation.

The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.



SECTION 1

Overview

Indian sandalwood is used in a variety of high value wood and oil applications



Logs



Oil




A vertically integrated and global business



 Plantation Operation
  Retail Outlet
  TFS Office
  Processing Plant
  Sales Representation

World's largest legal and sustainable plantations





SECTION 2

Unique Plantation Assets

Forestry operations have significant scale



12,182ha
OF PLANTATION



20,000km
OF IRRIGATION DRIP TAPE



63
PROPERTIES



over 50
OPERATING
BORES




39,000ha
OF MANAGED
LAND



over 500
WORKERS

Continuous investment over 17 years



Note 1: TFS Indirect and Direct Interests, 2012 to 2016
 Note 2: Biological asset valuation assumes an oil price of US\$2,800 per kg of oil

Biological assets will provide a substantial future income stream

Highly developed intellectual property

SITE SELECTION

- Semi-parasitic tree which only thrives in specific soil types
- Site selection designed to minimise climatic risks

SEED QUALITY

- Orchards developed over 15 years, provide genetically superior seeds
- Two purpose-built nurseries which produce 1.0m seedlings pa

SILVICULTURE

- Optimal deployment of host trees and irrigation techniques to maximize yield

PROCESSING

- Oil distillery produces the world's only pharmaceutical grade oil
- Processing facility with bespoke machinery and processes to efficiently extract heartwood

EXPERIENCE

- 17+ years experience of commercial plantation management
- Industry leading forestry team


15 years from planting to harvest
provides a substantial barrier to entry



SECTION 3

End Market Development


TFS to be the leading global supplier of sandalwood



Title: Forecast Global Supply of Legal and Authentic Indian Sandalwood 2015 – 2030

Source: Top tier global management consultancy firm, August 2016

High levels of latent demand to drive consumption



Title: Global Demand for Legal Indian Sandalwood

Source: Top tier global management consultancy firm, August 2016


Diverse markets with significant & growing demand

Territory	Market Segment	Size in 2025 (~ t / pa)	Supply deal
	Furniture & Handicraft	6,400	
	Temple & Worship	4,500	
	Perfumes & Cosmetics	4,000	
	Pharmaceutical	2,100	
	Mouth Freshener	2,100	
	Medicine	900	

Source: Top tier global management consultancy firm, August 2016

Vast majority of harvests to 2021 are forward sold

Negotiations now commencing for offtakes post 2021



Smoothed projected total harvest volumes (tonnes of heartwood) and contracted sales volumes 2016 - 2020




SECTION 4

Transformative FY17

Increased harvest leads to stronger product sales

Product Sales (wood and oil) in H1 set to increase 100% on H1 FY16



Results from multiple pharma trials due in 2017

- Santalis Pharmaceuticals is progressing with four FDA Phase 2 trials of prescription products containing Indian sandalwood oil
- Results due in H2 FY17 and positive results will generate significant shareholder value
- Santalis Pharmaceuticals expects to have at least one product in Phase 3 trials in 2017, which will provide the opportunity to unlock substantial value from this subsidiary

Code	Indication	Formulation Development	Phase I	Phase II	Phase III
VIR 001-00	HPV (skin warts)	—————→			CY2017
VIR 003-01	Molluscum (MSV)	—————→		Q2 CY17	
VIR 005-01	Oral Mucositis	—————→		Q2 CY17	
SAN 009-01	Eczema / AD	—————→		Q2 CY17	
SAN 021-00	Psoriasis	—————→		Q4 CY17	

Platform established for a transformational FY17

- ✓ Third annual harvest in 2016 delivered 310 tonnes of heartwood – in line with expectations and a tenfold increase on the 2015 harvest
- ✓ Forward sales of harvest will deliver an additional AU\$40+m of cash revenue in FY17
- ✓ Multi-year sale contracts mean the vast majority of harvests to 2021 have been forward sold
- ✓ Completion of Phase 2 pharmaceutical trials with potential to unlock significant value
- ✓ Strong balance sheet, with cash at 30 September 2016 of \$107m and significant operating cash generation expected in FY17

Guidance for FY17:

Cash EBITDA to increase by at least 25% on FY16



END